Journal: Arteriosclerosis, Thrombosis, and Vascular Biology

Article Title: Short-Term Stimulation of Calcium-Permeable Transient Receptor Potential Canonical 5–Containing Channels by Oxidized Phospholipids

doi: 10.1161/atvbaha.110.205666

Figure Lengend Snippet: Figure 6. Role of Gi/o signaling but not PAF receptors. Data are from intracellular Ca2 measurements from TRPC5- expressing HEK 293 cells (A-C) and VSMCs (D-F). Cells were pretreated with 1-g/mL pertussis toxin (PTX) or dena- tured (denat) PTX for 4 hours at 37°C. A through C, Responses were evoked by 3-mol/L PGPC (A, n/N3/9), 5-mol/L POVPC (B, n/N3/9), or 5-mol/L lyso- phosphatidylcholine (C, n/N3/18). D, A representative paired experiment showing responses to 3-mol/L PGPC after treat- ment with PTX or denatured PTX (N5 each). E, Responses were evoked by 3-mol/L PGPC or 5-mol/L POVPC (n/N4/20 each). F, Responses to 3-mol/L PGPC in cells preincubated and maintained in the presence of 100-mol/L WEB2086 or its vehicle (N6 each and representative of 3 independent experiments).

Article Snippet: Stocks of prostaglandin-E2 (PGE2) and ( )-15-deoxy-16R-hydroxy-17-cyclobutyl PGE1 ((R)-butaprost) at 10 mmol/L and 3-(4-[2-chlorophenyl]-9-methyl-6Hthieno[3,2-f](1,2,4)triazolo[4,3- ]diazepine-2-yl)-1-propanone (WEB2086; Tocris Bioscience) at 100 mmol/L were prepared in ethanol.

Techniques: Expressing

Journal: Arteriosclerosis, thrombosis, and vascular biology

Article Title: Biphasic regulation of transcription factor nuclear factor-kappaB activity in human endothelial cells by lysophosphatidylcholine through protein kinase C-mediated pathway.

doi: 10.1161/01.atv.18.4.568

Figure Lengend Snippet: Figure 9. Effect of PAF-receptor blocker on lysoPC-induced endothelial NF-kB activation. HUVECs were incubated for 60 minutes with lysoPC (15 mmol/L) in the presence of WEB 2086 (5.0 or 10.0 mmol/L), which is a specific PAF-receptor blocker. After the incubation, the nuclear proteins were extracted and analyzed by EMSA (7.5% gel). Arrow indicates the bands of NF-kB/DNA complex. Lane 1 (control), treated with vehicle; lane 2, treated with lysoPC alone; lane 3, treated with WEB 2086 (5.0 mmol/L)1lysoPC; lane 4, treated WEB 2086 (10.0 mmol/ L)1lysoPC. The result shown is representative of four indepen- dent experiments.

Article Snippet: Antibodies raised against p50, p65, RelB, and c-Rel were from Santa Cruz Biotechnology Inc. PAF receptor blocker (WEB 2086) was a gift from Boehringer Mannheim (Mannheim, Germany).

Techniques: Activation Assay, Incubation, Control